Page last updated: 2024-08-26

bosentan anhydrous and Prostatic Neoplasms

bosentan anhydrous has been researched along with Prostatic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carducci, MA; Lassiter, LK1
Lalich, M; Liu, G; McNeel, DG; Wilding, G1

Reviews

2 review(s) available for bosentan anhydrous and Prostatic Neoplasms

ArticleYear
Endothelin receptor antagonists in the treatment of prostate cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:5

    Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome

2003
Endothelin receptor antagonists in cancer therapy.
    Cancer investigation, 2007, Volume: 25, Issue:8

    Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides

2007